Schizophrenia studies

Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication according to the the ABCB1 Gene

Current recruitment status is unconfirmed.

This older record does not confirm current recruitment. No matching public CTIS record was confirmed using this identifier. Ask the research team for an up-to-date source.

Countries

Germany

Sponsor

HolsboerMaschmeyer NeuroChemie (HMNC) GmbH

2-year, Multicentre, Open-label, Flexible-dose Study to Evaluate the Safety and Tolerability of Cariprazine in the Treatment of Adolescent Patients with Schizophrenia

This study isn't currently recruiting.

This study transferred to CTIS. HopeStage uses that newer record for the displayed status. A country's status does not guarantee that an individual site accepts participants.

Countries

Bulgaria, Germany, Romania

Sponsor

Gedeon Richter Plc

A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients with Schizophrenia "ASPIRE OPEN-LABEL" (Aripiprazole...

This study isn't currently recruiting.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

France, United Kingdom, Belgium, + 7 others

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)

A Long-term, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Flexible-Dose Brexpiprazole as Maintenance Treatment in Adolescents (13-17 Years Old) With Schizophrenia

This study isn't currently recruiting.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

France, Bulgaria, Hungary, + 4 others

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc

A multi-center, double-blind, flexible-dose efficacy trial with Org 25935 versus placebo as add-on therapy in subjects with predominant, persistent negative symptoms of schizophrenia treated with a...

This study isn't currently recruiting.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

France, Austria, Czechia, + 1 other

Sponsor

NV Organon

A Phase 3, Multicenter, Double-Blind Comparison of LY2140023 and Aripiprazole in Patients with DSM-IV-TR Schizophrenia Followed by Open-Label Treatment with LY2140023

This study isn't currently recruiting.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Austria, Germany, Poland, + 1 other

Sponsor

Eli Lilly and Company

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects with Schizophrenia

This study isn't currently recruiting.

This study transferred to CTIS. HopeStage uses that newer record for the displayed status. A country's status does not guarantee that an individual site accepts participants.

Countries

Bulgaria, Croatia, Czechia, + 3 others

Sponsor

Neurocrine Biosciences, Inc.

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Adjunctive KarXT in Subjects with Inadequately Controlled Symptoms of Schizophrenia.

This study isn't currently recruiting.

This study transferred to CTIS. HopeStage uses that newer record for the displayed status. A country's status does not guarantee that an individual site accepts participants.

Countries

Bulgaria

Sponsor

Karuna Therapeutics, Inc.

A Prospective Randomized Open-label 6-Month Head-To-Head Trial to Compare Metabolic Effects of Paliperidone ER and Olanzapine in Subjects with Schizophrenia

This study isn't currently recruiting.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

France, United Kingdom, Estonia, + 7 others

Sponsor

Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium

A Controlled study of service level agreements between GPs and secondary services for the care of the long term mentally ill.

This study isn't currently recruiting.

Countries

United Kingdom

Sponsor

Record Provided by the NHS R&D 'Time-Limited' National Programme Register - Department of Health (UK)

A controlled study of short-term intensive community case management of severe mental illness: an assessment of its benefit to 'heavy users' of hospital services and cost effectiveness

This study isn't currently recruiting.

Countries

United Kingdom

Sponsor

NHS R&D Regional Programme Register - Department of Health (UK)

A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects with Schizophrenia

This study isn't currently recruiting.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Belgium, Austria, Bulgaria, + 9 others

Sponsor

Janssen-Cilag International N.V.